logo
  • Home
  • About Us
    • About Us
    • Why Raglan
    • Careers
  • Selected Transactions
  • Raglan IPO Projects
    • Raglan Pharmaceutical & Life Science Projects
    • Raglan Natural Resources
  • News
  • Contact us
  • Search

Open Orphan

Interim Results for 6 months ended 30 June 2020

by lynchski

New £4.3m Challenge Study Contract Win

September 28, 2020

Amryt Pharma – Update On Ongoing AP101 Trial

Amryt

by lynchski

Amryt Pharma – Grant Funding From Irish Government For AP103

Amryt

by lynchski

Amryt Pharma – LOJUXTA To Be Reimbursed In France

Amryt

by lynchski

Amryt Pharma – Interim Results

Amryt

by lynchski

Amryt Pharma - Amryt Receives Ind Approval From FDA for AP101

Amryt

by lynchski

Amryt Pharma – FDA Grants Pediatric Rare Disease Designation

Amryt

by lynchski

Amryt Pharma – Trading Update & Significant Momentum Building

Amryt

by lynchski

Amryt Pharma - NHS England Approves Funding For LOJUXTA

Amryt

by lynchski

  • 1
  • 2
© 2021 Raglan Capital. All rights reserved

Privacy Preference Center

Privacy Preferences